







an Open Access Journal by MDPI

Tumor Angiogenesis: An Update

Guest Editor:

Dr. Ruowen Ge

Department of Biological Sciences, National University of Singapore, Singapore 117558, Singapore

Deadline for manuscript submissions:

closed (15 March 2018)

Message from the Guest Editor

Dear Colleagues,

Since the approval of the first anti-angiogenesis drug, Avastin, for treatment of colon cancer in 2004, efficacy limitations of this class of anticancer drugs have generated questions and doubts on the effectiveness of the anti-angiogenesis approach for anticancer treatment. Recent discoveries in the biology of tumor angiogenesis indicate that many new factors and regulators are involved in the regulation of tumor angiogenesis such as the immune system, microRNA, ion channel, autophagy, etc. This Special Issue will focus on new discoveries in the biology and drug targeting of tumor angiogenesis. Both review and research articles are welcome.

We look forward to receiving your contributions. Dr. Ruowen Ge *Guest Editor*













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us